drugset
drugset / Trial / NCT03599193

A Bioavailability Study of DFD-03 Compared to Tazorac® in Patients With Moderate Acne Vulgaris

NCT03599193 ↗

Phase 2 Completed 58 enrolled Dr. Reddy's Laboratories Limited
RandomizedParallel-groupSingle-blindTreatment

Summary

This was a multicenter, randomized, multiple-dose, laboratory-blinded, open-label, 2-arm, parallel-arm study in subjects with moderate acne vulgaris.

Timeline

Start
2017-10-04
Primary completion
2018-04-30
Completion
2018-04-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Tazarotene Small molecule 0.1 % Topical

Indications

acne